Stephens Inc Alnylam Pharmaceuticals, Inc. Transaction History
Stephens Inc
- $6.94 Billion
- Q2 2025
A detailed history of Stephens Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Stephens Inc holds 635 shares of ALNY stock, worth $271,868. This represents 0.0% of its overall portfolio holdings.
Number of Shares
635Holding current value
$271,868% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
743Shares Held
110MCall Options Held
966KPut Options Held
866K-
Capital World Investors Los Angeles, CA16.7MShares$7.17 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$5.59 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.09 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$3.06 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.89 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $52.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...